Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)

Trial Profile

DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms DUOGLOBE
  • Sponsors AbbVie

Most Recent Events

  • 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
  • 26 Apr 2022 Results of a final analysis assessed the long term effectiveness and safety of levodopa-carbidopa intestinal gel during routine clinical practice in patients with advanced Parkinson's disease presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 26 Apr 2022 Results of a post hoc analysis assessed the effect of baseline disease severity on long-term effectiveness and safety of levodopa-carbidopa intestinal gel treatment in routine clinical practice presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top